HepatologyNews.net

Hepatology Xagena

Search results for "Ledipasvir"

Effective treatment for hepatitis C virus ( HCV ) genotype 1 infection in patients who have not had a sustained virologic response to prior Interferon-based therapy represents an unmet medical need. ...


In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor Sofosbuvir and the NS5A inhibitor Ledipasvir resulted in high rates of sustained virologic response a ...


High rates of sustained virologic response were observed among patients with hepatitis C virus ( HCV ) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor Sofosbuvir ...


Interferon-based treatment is not suitable for many patients with hepatitis C virus ( HCV ) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. L ...


Six treatment options are available in 2015 for patients infected with HCV genotype 1, including two IFN-containing regimens and four IFN-free regimens. The combination of Sofosbuvir and Ribavirin s ...


Interim results from one of the ongoing phase II studies of RG-101 for the treatment of hepatitis C virus infection ( HCV ) were announced. The study was designed to evaluate a shortened, 4-week tr ...


A pilot study found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a short-duration of six weeks had undetectable HCV after a 12 week follow-up. The ...


Data has demonstrated that choosing a different combination of direct-acting antiviral ( DAA ) treatment for hepatitis C can eradicate the virus at four weeks in patients who had already failed on pre ...


Real-world effectiveness data are needed to inform hepatitis C virus ( HCV ) treatment decisions. The uptake of Ledipasvir and Sofosbuvir ( LDV/SOF; Harvoni ) regimens across health care settings has ...